🇺🇸 FDA

Intelligence · Clinical Pipeline

Disc Medicine Pipeline

All ClinicalTrials.gov programs at Disc Medicine — phase, modality, and trial IDs.

Programs
308

Quick answer

Disc Medicine has 308 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. Saphnelo 300 mg concentrate for solution for infusion, Saphnelo placebo

    Disc Medicine

    Sjogren's disease

    phase 2 small molecule active

    1 trial

  2. Sitravatinib, Tislelizumab, Sitravatinib

    Disc Medicine

    Uveal melanoma

    phase 2 small molecule active

    1 trial

  3. Skyrizi 600 mg concentrate for solution for infusion

    Disc Medicine

    Inflammatory Bowel Disease (IBD)

    phase 2 small molecule active

    1 trial

  4. Skyrizi 600 mg concentrate for solution for infusion, Humira 40 mg solution for injection in pre-filled syringe

    Disc Medicine

    Inflammatory Bowel Disease (IBD)

    phase 2 small molecule active

    1 trial

  5. Sodium Chloride 0.9% w/v Intravenous Infusion BP Solution for Infusion., Cinryze 500 IU powder and solvent for solution for injection

    Disc Medicine

    aneurysmal subarachnoid hemorrhage

    phase 2 small molecule active

    1 trial

  6. Softisan 378, Cannabidiol

    Disc Medicine

    psychological disorders: PTSD; Anxiety disorders

    phase 2 small molecule active

    1 trial

  7. Subtyping Primary Aldosteronism with Para-chloro-2-[18F]fluoroethyl-etomidate ([18F]CETO)

    Disc Medicine

    Primary aldosteronism

    phase 2 other active

    1 trial

  8. TOPIRAMATE

    Disc Medicine

    human immunodeficiency virus 1 (HIV-1)

    phase 2 small molecule active

    1 trial

  9. Tecentriq 1 200 mg concentrate for solution for infusion

    Disc Medicine

    (Diffuse) Large B-cell Lymphoma

    phase 2 small molecule active

    1 trial

  10. Tecentriq 1 200 mg concentrate for solution for infusion, Tiragolumab

    Disc Medicine

    Squamous cell carcinoma of the anal canal

    phase 2 small molecule active

    1 trial

  11. Temozolomide Accord 180 mg hard capsules., Temozolomide Accord 250 mg hard capsules., Temozolomide Accord 5 mg hard capsules., Temozolomide SUN 5 mg hard capsules, Temozolomide Accord 20 mg hard capsules., Temozolomide SUN 180 mg hard capsules, Temozolomide SUN 250 mg hard capsules, Temozolomide Accord 100 mg hard capsules., Temozolomide SUN 140 mg hard capsules, Temozolomide Accord 140 mg hard capsules., Temozolomide SUN 100 mg hard capsules, Temozolomide SUN 20 mg hard capsules

    Disc Medicine

    Diffuse Midline Glioma, H3K27-altered

    phase 2 small molecule active

    1 trial

  12. Tiragolumab, Tecentriq 1 200 mg concentrate for solution for infusion

    Disc Medicine

    HNSCC, metastatic deficient mismatch repair (dMMR)/MSI-high (MSI-H) tumors, irresectable or metastatic melanoma, locally advanced or metastatic solid tumor

    phase 2 small molecule active

    1 trial

  13. YERVOY 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion.

    Disc Medicine

    castration-resistant prostate cancer

    phase 2 small molecule active

    1 trial

  14. Zr89

    Disc Medicine

    giant cell arteritis, rheumatoid arthritis

    phase 2 small molecule active

    1 trial

  15. [18F]-olaparib PET; Molecular imaging of DNA damage response by [18F]-olaparib PET

    Disc Medicine

    Head and neck squamous cell carcinoma (HNSCC)

    phase 2 other active

    1 trial

  16. [18F]Fluor-PEG-Folate

    Disc Medicine

    giant cell arteritis

    phase 2 small molecule active

    1 trial

  17. [18F]Tetrafluoroborate

    Disc Medicine

    Differentiated Thyroid Cancer

    phase 2 small molecule active

    1 trial

  18. [68Ga]FAPI-46

    Disc Medicine

    giant cell arteritis - polymyalgia rheumatica spectrum disease

    phase 2 small molecule active

    1 trial

  19. [68Ga]Ga-PentixaFor

    Disc Medicine

    Cardiac Sarcoidosis

    phase 2 small molecule active

    1 trial

  20. cRGD-ZW800-1

    Disc Medicine

    Squamous cell carcinoma of the larynx and hypopharynx

    phase 2 small molecule active

    1 trial

  21. cRGD-ZW800-1

    Disc Medicine

    Oral cancer

    phase 2 small molecule active

    1 trial

  22. 68GA-FAPI-46

    Disc Medicine

    Peritoneal metastases

    phase 1 small molecule active

    1 trial

  23. A phase I study investigating the local tolerability and pharmacokinetics of isoniazid (INH) inhalation by wet nebulization in patients with tuberculosis

    Disc Medicine

    Tuberculosis

    phase 1 other active

    1 trial

  24. Adoptive TIL therapy in combination with chemoimmunotherapy in advanced NSCLC patients

    Disc Medicine

    Respiratory tract diseases

    phase 1 other active

    1 trial

  25. AmBisome liposomale amfotericine B 50 mg, poeder voor oplossing voor infusie, TECHNETIUM (99MTC) PERTECHNETATE

    Disc Medicine

    Chronic pulmonary aspergillosis

    phase 1 small molecule active

    1 trial

  26. An open label, phase 1 study to evaluate the safety, feasibility and immunogenicity of an allogeneic, cell-based vaccine (VIDIDENCEL) in high grade serous ovarian cancer patients after primary treatment (ALISON)

    Disc Medicine

    High grade serous ovarian cancer

    phase 1 other active

    1 trial

  27. Bio-equivalence of Rosuvastatin 10 mg

    Disc Medicine

    Healthy volunteers

    phase 1 other active

    1 trial

  28. Click-cleavable imaging in HER2-positive cancers (CleavHER trial).

    Disc Medicine

    HER2-positive tumors

    phase 1 other active

    1 trial

  29. Coadministration of GA2 Sporozoites With Adjuvants (CoGA)

    Disc Medicine

    Falciparum malaria

    phase 1 other active

    1 trial

  30. Combining drug-eluting bead chemoembolization and radioembolization for treatment of colorectal liver metastases: DEBIR90Y study

    Disc Medicine

    colorectal liver metastases

    phase 1 other active

    1 trial

  31. DISC-0974

    Disc Medicine

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial

  32. DISC-0974

    Disc Medicine

    Chronic Kidney Diseases

    phase 1 small molecule completed

    1 trial

  33. DISC-3405

    Disc Medicine

    Sickle Cell Disease

    phase 1 small molecule active

    1 trial

  34. DISC-3405

    Disc Medicine

    Healthy Volunteer

    phase 1 small molecule completed

    1 trial

  35. Dendritic cell therapy combined with surgery in mesothelioma (ENSURE)

    Disc Medicine

    Adult patients diagnosed with resectable epithelioid MPM, following first-line chemotherapy.

    phase 1 other active

    1 trial

  36. Detection of tumor tiSsue in pEritoneal metastases of coLorectal origin using a VEGF-targeted optical fluoresCent imaging tracer during diagnosTic laparoscopy

    Disc Medicine

    peritoneal metastases of colorectal origin

    phase 1 other active

    1 trial

  37. Dual-Wavelength Quantitative Fluorescence Endoscopy for Optical PD-1 and PD-L1 Imaging in Locally Advanced Esophageal Cancer: A Phase I Multicenter Feasibility and Safety Study

    Disc Medicine

    Esophageal cancer

    phase 1 other active

    1 trial

  38. Evaluating PD-1/PD-L1 in rectal cancer by quantitative fluorescence molecular endoscopy.

    Disc Medicine

    Locally advanced rectal cancer

    phase 1 other active

    1 trial

  39. Evaluation of the Novel Therapeutic Hepatitis B Virus Synthetic Long Peptide Vaccination ISA104 (HEB-PEP)

    Disc Medicine

    chronic Hepatitis B

    phase 1 other active

    1 trial

  40. GRoningen Early-PD Ambroxol Treatment Pharmacokinetics

    Disc Medicine

    Parkinson's disease

    phase 1 other active

    1 trial

  41. INTERACT MESO: Intraperitoneal Paclitaxel for Patients with Primary Malignant Peritoneal Mesothelioma – a Phase I/II Dose Escalation and Safety Study

    Disc Medicine

    Patients with malignant peritoneal mesothelioma

    phase 1 other active

    1 trial

  42. INTERACT stomach

    Disc Medicine

    Stomach Cancer with metastasis in the peritoneum

    phase 1 other active

    1 trial

  43. Improving Peptide Receptor Radionuclide Therapy with PARP inhibitors

    Disc Medicine

    locally advanced or metastatic, well-differentiated gastro-enteropancreatic neuroendocrine tumors.

    phase 1 other active

    1 trial

  44. Irinotecan Accord 20 mg/ml concentraat voor oplossing voor infusie

    Disc Medicine

    Gastric cancer

    phase 1 small molecule active

    1 trial

  45. MCA-derived MSC therapy in renal transplant recipients

    Disc Medicine

    Rejection transplanted kidney, BPAR

    phase 1 other active

    1 trial

  46. MIRROR; Multispectral and bimodal fluorescent guided surgery (FGS) of high-grade glioma for refining margin assessment: A phase 1 dose finding study using Cetuximab-IRDye800CW- combined with 5-ALA

    Disc Medicine

    Glioblastoma

    phase 1 other active

    1 trial

  47. Molecular imaging with FAPI for diagnosing the CSM4 colorectal cancer subtype

    Disc Medicine

    Colorectal cancer, liver metastases

    phase 1 other active

    1 trial

  48. Optical PD-L1 imaging using Quantitative Fluorescence Endoscopy in locally advanced esophageal cancer using durvalumab-680LT: a phase I multicenter feasibility and safety study

    Disc Medicine

    Esophageal cancer

    phase 1 other active

    1 trial

Frequently asked questions

How many pipeline programs does Disc Medicine have?

308 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.